Schrodinger, Inc. (SDGR) Transition to Licensing Model Triggers Robust Revenue Growth

Schrodinger Inc. (NASDAQ:SDGR) is one of the best cancer stocks to invest in now. On February 25, Schrodinger Inc. (NASDAQ:SDGR) delivered solid fourth-quarter and full-year 2025 results characterized by robust revenue growth. The company also announced it is accelerating its transition to a licensing model to establish a more predictable, higher-visibility revenue stream.

Full-year revenue was up by 23.3% to $255.9 million, driven by a 10.6% increase in software revenue. Drug discovery revenue more than doubled to $56.4 million from $27.2 million in the prior year. However, fourth-quarter revenue was down 1.2% year over year to $87.2 million, as software revenue fell 13% to $69.3 million. Drug discovery in the quarter more than doubled to $18 million compared to $8.7 million in the same quarter of the prior year.

“Our success is enabled by our transformative platform that integrates ground-truth, physics-based simulation with leading-edge AI and machine learning. Looking ahead to 2026, we are poised to scale our impact through new platform enhancements and the commercial launch of our predictive toxicology solution,” said Ramy Farid, Ph.D., chief executive officer of Schrödinger

Full-year net loss shrank to $103.3 million compared to $187.1 million delivered in 2024. Schrodinger bounced to profitability in the fourth quarter of FY25, reporting net income of $32.5 million, compared with a net loss of $40.2 million in the fourth quarter of 2024.

The company also issued impressive 2026 guidance, expecting software revenue to range between $218 and $228 million, representing 10-15% growth. Drug discovery revenue is expected to range between $55 million and $65 million.

Schrödinger, Inc. (NASDAQ:SDGR) is a healthcare technology company that provides a physics-based software platform for molecular simulation, enabling the discovery of novel, high-quality molecules for drug development and materials science. The company’s platform is designed to accelerate research and development (R&D) by predicting molecular properties, reducing the time and cost required to bring new products to market.

While we acknowledge the potential of SDGR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Manufacturing Stocks to Invest In Now and 11 AI Stocks That Will Go to the Moon.